Barclays
AVIR icon

Barclays’s Atea Pharmaceuticals AVIR Stock Holding History

Barclays’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$866K Sell
160,946
-82,044
-34% -$377K ﹤0.01% 2839
2025
Q4 		$867K Buy
242,990
+1,526
+0.6% +$4.85K ﹤0.01% 3539
2025
Q3 		$700K Sell
241,464
-20,310
-8% -$69.4K ﹤0.01% 3594
2025
Q2 		$942K Buy
261,774
+90,462
+53% +$270K ﹤0.01% 3379
2025
Q1 		$512K Sell
171,312
-28,801
-14% -$89.9K ﹤0.01% 3519
2024
Q4 		$670K Buy
200,113
+23,036
+13% +$76.6K ﹤0.01% 3647
2024
Q3 		$593K Buy
177,077
+75,624
+75% +$274K ﹤0.01% 3671
2024
Q2 		$336K Sell
101,453
-44,079
-30% -$164K ﹤0.01% 3276
2024
Q1 		$588K Sell
145,532
-51,555
-26% -$202K ﹤0.01% 3489
2023
Q4 		$601K Buy
197,087
+171,468
+669% +$519K ﹤0.01% 3769
2023
Q3 		$76.9K Buy
25,619
+10,348
+68% +$35.2K ﹤0.01% 3686
2023
Q2 		$57.1K Sell
15,271
-23,488
-61% -$87.9K ﹤0.01% 3775
2023
Q1 		$130K Buy
38,759
+12,677
+49% +$51.4K ﹤0.01% 4042
2022
Q4 		$125K Sell
26,082
-10,941
-30% -$55.3K ﹤0.01% 4100
2022
Q3 		$211K Sell
37,023
-9,917
-21% -$75.9K ﹤0.01% 3166
2022
Q2 		$333K Sell
46,940
-15,070
-24% -$103K ﹤0.01% 3125
2022
Q1 		$448K Buy
+62,010
New +$421K ﹤0.01% 2975

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Barclays's AVIR Position: Q1 2026 in Review

Barclays reduced its Atea Pharmaceuticals (AVIR) stake by 34% in Q1 2026, selling an estimated $377K and leaving 160,946 shares worth $866K. The position accounts for ﹤0.01% of the portfolio, ranked #2839.

Barclays first reported a position in AVIR in Q1 2022 and has held it in 17 quarters since. The position peaked at $942K in Q2 2025. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • Barclays held 160,946 shares of Atea Pharmaceuticals worth $866K as of Q1 2026.
  • Barclays sold 82,044 Atea Pharmaceuticals shares in Q1 2026, an estimated $377K.
  • Atea Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2839 holding.
  • Barclays first reported a position in Atea Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Atea Pharmaceuticals position peaked at $942K in Q2 2025.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.